Table 1 Car clinical trials
From: Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Trial | Outcomes | Adverse effects | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Target | Agent | Trial ID + references | Status | Phase | Study population | Enrollment (N) | ORR (%) | Median PFS (months) | Grade ≥ 3 CRS (%) | Grade 3 NTX (%) |
BCMA | CAR-BCMA | NCT02215967 [37] | Completed | 1 | RRMM | 24 | 81 | 7.75 | 25 | 4 |
BCMA | CAR T-BCMA (UPenn) | NCT02546167 [46] | Completed | 1 | HRMM | 25 | 48 | 2.7 | 32 | 12 |
BCMA | BCMA CAR | NCT04650724 [109] | Completed | 1 | RRMM (extramedullary) | 3 (data published for 1 patient) | 100 | 3 | 0 | 0 |
BCMA | Idecabtagene vicleucel (bb2121) | NCT02658929 (CRB-401) [110] | Active, not recruiting | 1 | RRMM | 67 | 76 | 8.8 | 6 | 3 |
BCMA | Idecabtagene vicleucel (bb2121) | NCT04196491 (KarMMa-4) [111] | Recruiting | 1 | NDMM, HRMM | 60 | 76 | 8.8 | 6 | 3 |
BCMA | bb21217 | NCT03274219 (CRB-402) [112] | Active, not recruiting | 1 | RRMM | 72 | 55 | 11.9 | 4 | 6 |
BCMA | Zevorcabtagene autoleucel (CT053) | NCT03975907 (LUMMICAR-1) [113] | Recruiting | 1 | RRMM | 62 | 87.5 | 18.8 | 6 | 3 |
BCMA | Zevorcabtagene autoleucel (CT053) | NCT03302403 [114] | Active, not recruiting | 1 | RRMM | 18 | 87.5 | Not yet reached | 0 | 4 |
BCMA | Zevorcabtagene autoleucel (CT053) | NCT03716856 [114] | Active, not recruiting | 1 | RRMM | 11 | 87.5 | Not yet reached | 0 | 4 |
BCMA | Zevorcabtagene autoleucel (CT053) | NCT03380039 [114] | active, not recruiting | 1 | RRMM | 6 | 87.5 | Not yet reached | 0 | 4 |
BCMA | C-CAR088 | NCT04322292 [115] | Recruiting | 1 | RRMM | 10 | 95.2 | Not yet reached | 5 | 0 |
BCMA | C-CAR088 | NCT03815383 [115] | Unknown | 1 | RRMM | 12 | 95.2 | Not yet reached | 5 | 0 |
BCMA | C-CAR088 | NCT03751293 [115] | Unknown | 1 | RRMM | 10 | 95.2 | Not yet reached | 5 | 0 |
BCMA | C-CAR088 | NCT04295018 [115] | Unknown | 1 | RRMM | 10 | 95.2 | Not yet reached | 5 | 0 |
BCMA | BCMA nanobody CARs | NCT03661554 [116] | Unknown | 1 | RRMM | 15 | 88.2 | 12.1 | 2.9 | 0 |
BCMA | FCARH143 (53) | NCT03338972 | Active, not recruiting | 1 | RRMM | 28 | 100 | Not yet reached | 6 | 0 |
BCMA | HRAIN Biotechnology | NCT03093168 [117] | Unknown | 1 | RRMM | 10 | 86 | Not yet reached | 0 | 0 |
BCMA | IM21 CAR T | NCT04537442 | Recruiting | 1 | RRMM, age ≥ 60 | 10 | NA | NA | NA | NA |
BCMA | IM21 CAR T | NCT03711864 | Recruiting | 1 | RRMM | 15 | NA | NA | NA | NA |
BCMA | BCMA-specific CAR T + gamma-secretase inhibitor LY3039478 | NCT03502577 [55] | Suspended | 1 | RRMM | 18 | NA | NA | NA | NA |
BCMA | KITE-585 | NCT03318861 | Active, not recruiting | 1 | RRMM | 17 | 7 | 1 | 21 | 21 |
BCMA | CC-98633 | NCT04394650 | Recruiting | 1 | RRMM | 80 | NA | NA | NA | NA |
BCMA | Human BCMA-targeted T Cells | NCT04003168 | Recruiting | 1 | RRMM | 18 | NA | NA | NA | NA |
BCMA | BCMA CAR T cells | NCT05150522 | Recruiting | 1 | RRMM | 10 | NA | NA | NA | NA |
BCMA | anti-BCMA CAR T (carbiogene) | NCT04637269 | Recruiting | 1 | RRMM | 16 | NA | NA | NA | NA |
BCMA | BCMA CAR T + immune inhibitors | NCT03943472 | Recruiting | 1 | RRMM | 10 | NA | NA | NA | NA |
BCMA | BCMA-UCART | NCT03752541 | Recruiting | 1 | RRMM | 20 | NA | NA | NA | NA |
BCMA | CXCR4-modified anti-BCMA CAR T cells | NCT04727008 | Not yet recruiting | 1 | RRMM | 12 | NA | NA | NA | NA |
BCMA | BCMA-targeted CAR T cells | NCT04670055 | Not yet recruiting | 1 | RRMM | 50 | NA | NA | NA | NA |
BCMA | BCMA-CAR T cells | NCT04186052 | Unknown | 1 | RRMM | 10 | NA | NA | NA | NA |
BCMA | NEXI-002 | NCT04505813 | Recruiting | 1 | RRMM | 22 | NA | NA | NA | NA |
BCMA | BCMA CAR T | NCT03559764 | Unknown | 1 | RRMM | 20 | NA | NA | NA | NA |
BCMA | BCMA CAR T | NCT04626752 | Recruiting | 1 | RRMM | 50 | NA | NA | NA | NA |
BCMA | CBG-002 | NCT04706936 | Recruiting | 1 | RRMM | 25 | NA | NA | NA | NA |
BCMA | FHVH-BCMA-T | NCT03602612 [58] | Active, not recruiting | 1 | RRMM | 35 | NA | NA | NA | NA |
BCMA | HB10101 | NCT04720313 | Recruiting | 1 | RRMM | 48 | NA | NA | NA | NA |
BCMA | CAR T-ddBCMA | NCT04155749 | Recruiting | 1 | RRMM | 65 | NA | NA | NA | NA |
BCMA | BCMA CAR T | NCT03322735 | Unknown | 1 | RRMM | 10 | NA | NA | NA | NA |
BCMA | CAR T re-treatment | NCT03672253 | Unknown | 1 | RRMM | 20 | NA | NA | NA | NA |
BCMA | CT103A (IBI326) | NCT05066646 (FUMANBA-1) | Recruiting | 1 | RRMM | 132 | 94.9 | Not yet reached | 3 | 0 |
BCMA | CT103A (IBI326) | NCT05201118 | Not yet recruiting | 1 | RRMM (extramedullary) | 20 | NA | NA | NA | NA |
BCMA | CT103A (IBI326) | NCT05181501 | Not yet recruiting | 1 | NDMM, HRMM | 20 | NA | NA | NA | NA |
BCMA | LCAR-BCX | NCT04601935 | Recruiting | 1 | RRMM | 34 | NA | NA | NA | NA |
BCMA | PHE885 | NCT04318327 [118] | Recruiting | 1 | RRMM | 48 | NA | NA | NA | 0 |
BCMA | JWCAR129 | NCT04677452 | Recruiting | 1 | RRMM | 24 | NA | NA | NA | NA |
BCMA | LCAR-B4822M | NCT03674463 | Unknown | 1 | RRMM | 10 | NA | NA | NA | NA |
BCMA | ALLO-715 CAR + ALLO-647 (anti-CD52 mAb) | NCT04093596 (UNIVERSAL) | Active, not recruiting | 1 | RRMM | 132 | NA | NA | NA | NA |
BCMA | BCMA nanobody CAR T cells | NCT03664661 | Recruiting | 1 | RRMM | 15 | NA | NA | NA | NA |
BCMA | P-BCMA-ALLO1 | NCT04960579 | Not yet recruiting | 1 | RRMM | 40 | NA | NA | NA | NA |
BCMA | MCARH171  + lenalidomide | NCT03070327 [119] | Active, not recruiting | 1 | RRMM | 20 | 64 | NA | 20 | 0 |
BCMA and/or CD19 | anti-BCMA-CD19 CAR T | NCT03767725 | Unknown | 1 | RRMM | 10 | NA | NA | NA | NA |
BCMA and/or CD19 | Autologous BCMA CAR T cells and CD19 CAR T cells | NCT04194931 | Unknown | 1 | RRMM | 20 | NA | NA | NA | NA |
BCMA and CD19 | CAR T-BCMA + huCART19 | NCT03549442 | Active, not recruiting | 1 | HRMM | 40` | NA | NA | NA | NA |
BCMA or CD19 | CD19/BCMA-targeted CAR T cells + dasatinib | NCT04603872 | Recruiting | 1 | RRMM | 120 | NA | NA | NA | NA |
CD138 or integrin β7 or SLAMF7 or CD38 or BCMA | CAR T therapy | NCT03778346 | Recruiting | 1 | RRMM | 30 | NA | NA | NA | NA |
BCMA x CD19 | BCMA/CD19 dual-target CAR T cell | NCT04412889 | Not yet recruiting | 1 | RRMM | 18 | NA | NA | NA | NA |
BCMA x CD19 | GC012F | NCT04236011 [120] | Recruiting | 1 | RRMM | 33 | 94.7 | Not yet reached | 10.5 | 0 |
BCMA x CD19 | GC012F | NCT04617704 | Active, not recruiting | 1 | NDMM, HRMM | 15 | NA | NA | NA | NA |
BCMA x CD19 | GC012F | NCT04182581 [120] | Unknown | 1 | RRMM | 18 | 94.7 | Not yet reached | 10.5 | 0 |
BCMA x CD19 | BCMA/CD19 CAR T | NCT04795882 | Not yet recruiting | 1 | RRMM | 24 | NA | NA | NA | NA |
BCMA x CD19 | BCMA-CD19 cCAR T cells | NCT04162353 [52] | Recruiting | 1 | RRMM | 12 | 95 | 8 | NA | NA |
BCMA x CD19 | Anti-CD19/BCMA CAR T cells | NCT03706547 | Recruiting | 1 | RRMM | 20 | NA | NA | NA | NA |
BCMA x TACI | TriPRIL CAR T Cells | NCT05020444 | Recruiting | 1 | RRMM | 18 | NA | NA | NA | NA |
BCMA x TACI | APRIL CAR T cells | NCT04657861 | Not yet recruiting | 1 | RRMM | 36 | NA | NA | NA | NA |
BCMA x TACI | AUTO2 | NCT03287804 [121] | Terminated | 1 | RRMM | 12 | 43 | Not published | 0 | 0 |
BCMA x SLAMF7 | CS1/BCMA Bispecific CAR | NCT04662099 | Recruiting | 1 | RRMM | 24 | NA | NA | NA | NA |
BCMA x SLAMF7 | BCMA-CS1 cCAR T cells | NCT04156269 | Unknown | 1 | RRMM | 12 | NA | NA | NA | NA |
BCMA | Idecabtagene vicleucel (bb2121) | NCT04855136 (KarMMa-7) | Recruiting | 1/2 | RRMM | 415 | NA | NA | NA | NA |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT03548207 (CARTITUDE-1) [122] | Active, not recruiting | 1/2 | RRMM | 126 | 98 | Not yet reached | 4 | 10 |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT03090659 (LEGEND-2) [123] | Active, not recruiting | 1/2 | RRMM | 100 | 88 | 19.9 | 41 | 0 |
BCMA | Orvacabtagene autoleucel (JCARH125) | NCT03430011 (EVOLVE) [124] | Active, not recruiting | 1/2 | RRMM | 169 | 91 | Not yet reached | 2 | 4 |
BCMA | Zevorcabtagene autoleucel (CT053) | NCT03915184 (LUMMICAR-2) [125] | Recruiting | 1/2 | RRMM | 105 | 100 | Not yet reached | 0 | 0 |
BCMA | P-BCMA-101 | NCT03288493 (PRIME) | Active, not recruiting | 1/2 | RRMM | 220 | 57 | Not yet reached | 2 | 0 |
BCMA | DESCARTES 08 | NCT04816526 | Recruiting | 1/2 | NDMM, HRMM | 30 | NA | NA | NA | NA |
BCMA | DESCARTES 11 | NCT03994705 | Recruiting | 1/2 | RRMM | 18 | NA | NA | NA | NA |
BCMA | ARI0002h | NCT04309981 [126] | Recruiting | 1/2 | RRMM | 36 | NA | NA | NA | NA |
BCMA | PBCAR269A + nirogacestat (gamma-secretase inhibitor) | NCT04171843 | Recruiting | 1/2 | RRMM | 48 | NA | NA | NA | NA |
BCMA | BCMA CAR T cells | NCT04272151 | Recruiting | 1/2 | RRMM | 40 | NA | NA | NA | NA |
BCMA | BCMA-targeted prime CAR T cells | NCT04776330 | Recruiting | 1/2 | RRMM | 80 | NA | NA | NA | NA |
BCMA | BCMA CAR T cells | NCT04271644 | Recruiting | 1/2 | RRMM | 80 | NA | NA | NA | NA |
BCMA | Anti-BCMA-CAR Transduced T cells | NCT02954445 | Unknown | 1/2 | RRMM | 45 | NA | NA | NA | NA |
BCMA | SENL-B19 | NCT03312205 [127] | Recruiting | 1/2 | RRMM | 50 | NA | NA | 19 | NA |
BCMA | ALLO-605 CAR + ALLO-647 (anti-CD52 mAb) | NCT05000450 | Active, not recruiting | 1/2 | RRMM | 136 | NA | NA | NA | NA |
BCMA | spCART-269 | NCT04500431 | Recruiting | 1/2 | RRMM | 10 | NA | NA | NA | NA |
CD138 and BCMA and CD19 | CAR T-138/BCMA/19/MORE | NCT03196414 [128] | Recruiting | 1/2 | RRMM | 10 | 80 | NA | NA | 0 |
NY-ESO-1 + CD38 + BCMA + CD19 | MULTI-target CAR T cell | NCT03638206 | Recruiting | 1/2 | RRMM | 73 | NA | NA | NA | NA |
BCMA, CD38, CD138, CD56 | MULTI-CAR T | NCT03271632 | Recruiting | 1/2 | RRMM | 20 | NA | NA | NA | NA |
BCMA x CD38 | Dual Specificity CD38 and BCMA CAR T | NCT03767751 | Recruiting | 1/2 | RRMM | 80 | NA | NA | NA | NA |
BCMA x CD19 | GC012F | NCT04935580 | Recruiting | 1/2 | NDMM, HRMM | 20 | NA | NA | NA | NA |
BCMA x CD19 | CD19-BCMA CAR T cells | NCT04714827 | Recruiting | 1/2 | RRMM | 24 | NA | NA | NA | NA |
BCMA and CD19 | anti-CD19 and anti-BCMA CAR + auto-HSCT | NCT03455972 | Recruiting | 1/2 | NDMM, HRMM | 15 | NA | NA | NA | NA |
BCMA | Idecabtagene vicleucel (bb2121) | NCT03361748 (KarMMa) [129] | Active, not recruiting | 2 | RRMM | 149 | 73 | 8.8 | 5 | 3 |
BCMA | Idecabtagene vicleucel (bb2121) | NCT03601078 (KarMMa-2) | Recruiting | 2 | NDMM, RRMM | 181 | NA | NA | NA | NA |
BCMA | Idecabtagene vicleucel (bb2121) | NCT05032820 | Not yet recruiting | 2 | RRMM | 40 | NA | NA | NA | NA |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT04133636 (CARTITUDE-2) [130] | Recruiting | 2 | NDMM, RRMM | 160 | 95 | Not yet reached | 10 | 0 |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT03758417 (CARTIFAN-1) | Recruiting | 2 | RRMM | 130 | NA | NA | NA | NA |
BCMA | DESCARTES 08 | NCT03448978 | Recruiting | 2 | RRMM | 30 | NA | NA | NA | NA |
BCMA | DESCARTES 11 | NCT04436029 | Recruiting | 2 | NDMM, HRMM | 30 | NA | NA | NA | NA |
BCMA | PHE885 | NCT05172596 | Not yet recruiting | 2 | RRMM | 100 | NA | NA | NA | NA |
BCMA | BMCA-targeted CAR T | NCT03931421 | Recruiting | 2 | RRMM | 30 | NA | NA | NA | NA |
BCMA x PD-1 | BCMA-PD-1-CAR T Cell | NCT04162119 | Recruiting | 2 | RRMM | 30 | NA | NA | NA | NA |
BCMA | Idecabtagene vicleucel (BB2121) | NCT03651128 (KarMMa-3) [131] | Recruiting | 3 | RRMM | 381 | NA | NA | NA | NA |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT04181827 (CARTITUDE-4) | Active, not recruiting | 3 | RRMM | 419 | NA | NA | NA | NA |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT04923893 (CARTITUDE-5) | Recruiting | 3 | ASCT ineligible MM patients | 650 | NA | NA | NA | NA |
BCMA | BCMA-directed CAR T cells + lenalidomide | NCT04287660 | Recruiting | 3 | NDMM | 20 | NA | NA | NA | NA |
BCMA | Ciltacabtagene autoleucel (JNJ-68284528, LCAR-B38M) | NCT05201781 | Not yet recruiting | 4 | Janssen-sponsored cilta-cel patients | 228 | NA | NA | NA | NA |
CD19 | CTL019 | NCT02135406 [91] | Completed | 1 | RRMM | 10 | 80 | Not published | 0 | 0 |
CD19 | CAR T-19 cells | NCT02794246 | Terminated | 2 | RRMM | 6 | NA | NA | NA | NA |
SLAMF7 | CS1-CAR T Therapy | NCT03710421 | Recruiting | 1 | RRMM | 30 | NA | NA | NA | NA |
SLAMF7 | UCARTCS1A | NCT04142619 (MELANI-01) | Recruiting | 1 | RRMM | 18 | NA | NA | NA | NA |
SMLAF7 | CS1-targeted CAR T cells | NCT04541368 | Not yet recruiting | 1 | RRMM | 50 | NA | NA | NA | NA |
SLAMF7 | Anti-SLAMF7 CAR T cells | NCT03958656 | Completed | 1 | RRMM | 13 | NA | NA | NA | NA |
SLAMF7 | SLAMF7 CAR T | NCT04499339 (CARAMBA-1) | Recruiting | 1/2 | RRMM | 38 | NA | NA | NA | NA |
GPRC5D | CAR-GPRC5D | NCT05219721 | Not yet recruiting | 1 | RRMM | 18 | NA | NA | NA | NA |
GPRC5D | GPRC5D-CAR T | NCT05016778 | Recruiting | 1 | RRMM | 15 | NA | NA | NA | NA |
GPRC5D | MCARH109 | NCT04555551 | Active, not recruiting | 1 | RRMM | 17 | 83 | Not yet published | 8 | 0 |
CD138 | CAR138 T Cells | NCT03672318 | Recruiting | 1 | RRMM | 33 | NA | NA | NA | NA |
CD138 | CAR T-138 | NCT01886976 [95] | Recruiting | 1/2 | RRMM | 10 | 80 | NA | 0 | 0 |
CD38 | CAR2 Anti-CD38 A2 CAR T Cells | NCT03464916 | Active, not recruiting | 1 | RRMM | 72 | NA | NA | NA | NA |
CD70 | CD70 CAR | NCT04662294 | Recruiting | 1 | RRMM | 108 | NA | NA | NA | NA |
NKG2D | CM-CS1 T cell infusion | NCT02203825 [85] | Completed | 1 | RRMM | 12 | NA | NA | 0 | 0 |
NKG2D | NKR-2 (CYAD-01) | NCT03018405 (THINK) [86] | Recruiting | 1/2 | RRMM | 146 | 46 | NA | 18.8 | 0 |
TnMuc1 | CAR T-TnMUC1 | NCT04025216 [94] | Recruiting | 1 | RRMM | 112 | NA | NA | 0 | 0 |
CD44v6 | MLM-CAR44.1Â T cells | NCT04097301 | Terminated | 1/2 | RRMM | 48 | NA | NA | NA | NA |
MMG49 | OPC-415 | NCT04649073 | Recruiting | 1/2 | RRMM | 49 | NA | NA | NA | NA |
PD-1 x not published | Novel CAR T | NCT04191941 | Unknown | 1 | RRMM | 9 | NA | NA | NA | NA |
no data published | C-4–29 Dual-target CAR T cells | NCT04861480 | Recruiting | NA | RRMM | 18 | NA | NA | NA | NA |